2m 2m 2m 2m 2m 2m 2m
Enanta Pharm (ENTA)
NASDAQ
$11.25-$0.78 (-6.48%)
Price as of Jun 03, 2026 4:10 PM EDT- $382.7MMarket Cap
- 67.32%1-Year Change
- BiotechnologyIndustry
Enanta Pharm (ENTA)
$11.25-$0.78 (-6.48%)
Annual
Quarterly
09/30/2025 | 09/30/2024 | 09/30/2023 | 09/30/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 65.3M -3.42% | 67.6M -14.61% | 79.2M -8.07% | 86.2M -11.24% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 65.3M -3.42% | 67.6M -14.61% | 79.2M -8.07% | 86.2M -11.24% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -106.7M -18.81% | -131.5M -19.60% | -163.5M -0.61% | -164.5M -5.51% | |
Depreciation and Amortization Expense | 4.6M +96.32% | 2.3M -1.48% | 2.4M -20.25% | 3.0M -10.83% | |
Total Operating Expenses | 150.7M -20.42% | 189.3M -12.52% | 216.4M +3.05% | 210.0M +1.62% | |
Operating Profit | -85.3M -29.86% | -121.7M -11.31% | -137.2M +10.79% | -123.8M +13.02% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -8.2M +1,120.24% | -672,000 -86.95% | -5.1M N/A | N/A N/A | |
Interest Income and Expense and Net | -8.2M +1,120.24% | -672,000 -86.95% | -5.1M N/A | 0 N/A | |
Total Nonoperating Income and Expense | 1.8M -53.88% | 3.9M -37.17% | 6.2M +275.12% | 1.7M -16.95% | |
Income before Taxes | -83.5M -29.07% | -117.8M -10.08% | -131.0M +7.21% | -122.2M +13.58% | |
Income Taxes | -1.7M -4.76% | -1.7M -161.79% | 2.8M +751.50% | -433,000 -98.49% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -81.9M -29.43% | -116.0M -13.28% | -133.8M +9.91% | -121.8M +54.13% | |
Net Income from Continuing Operations Applicable to Common | -83.5M -29.07% | -117.8M -10.08% | -131.0M +7.21% | -122.2M +13.58% | |
Basic EPS and Net Income | -3.84 -29.93% | -5.48 -14.11% | -6.38 +7.95% | -5.91 +50.77% | |
Diluted EPS and Net Income | -3.84 -29.93% | -5.48 -14.11% | -6.38 +7.95% | -5.91 +50.77% | |
Basic Weighted Average Shares | 21,336 +0.85% | 21,157 +0.90% | 20,969 +1.78% | 20,603 -99.90% | |
Diluted Weighted Average Shares | 21,336 +0.85% | 21,157 +0.90% | 20,969 +1.78% | 20,603 -99.90% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 32.3M -13.25% | 37.2M -56.40% | 85.4M +94.09% | 44.0M -23.10% | |
Short-Term Investments | 156.6M -25.78% | 211.0M -25.86% | 284.5M +38.63% | 205.2M +9.87% | |
Cash and Cash Equivalents and Short-Term Investments | 188.9M -23.90% | 248.2M -32.91% | 369.9M +48.42% | 249.2M +2.14% | |
Total Current Assets | 204.3M -31.85% | 299.9M -29.08% | 422.8M +35.63% | 311.7M -2.29% | |
Accumulated Depreciation | 23.8M -4.96% | 25.0M +5.48% | 23.7M +8.63% | 21.9M +15.49% | |
Property and Plant and Equipment and Net | 35.4M +8.28% | 32.7M +174.25% | 11.9M +93.08% | 6.2M +3.87% | |
Total Long-Term Assets | 92,000 -2.13% | 94,000 -88.29% | 803,000 +15.37% | 696,000 +656.52% | |
Total Assets | 280.7M -25.47% | 376.7M -18.52% | 462.3M +23.14% | 375.4M -14.44% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 48.6M -15.61% | 57.5M -8.36% | 62.8M +110.50% | 29.8M -17.54% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 260,000 +12.55% | 231,000 -65.16% | 663,000 +46.04% | 454,000 -18.64% | |
Total Liabilities | 216.0M -12.84% | 247.8M +0.94% | 245.5M +354.06% | 54.1M +37.38% | |
Retained Earnings | -404.9M +25.35% | -323.0M +56.06% | -207.0M +182.86% | -73.2M -250.65% | |
Total Stockholders Equity | 64.7M -49.76% | 128.8M -40.57% | 216.7M -32.55% | 321.3M -19.55% | |
Total Shares Outstanding | 21.4M +0.91% | 21.2M +0.64% | 21.1M +1.29% | 20.8M +2.73% | |
Cash Flow | |||||
Cash from Operating Activities | -19.3M -75.53% | -78.8M -23.64% | -103.2M +21.67% | -84.8M +21.12% | |
Capital Expenditures | 12.9M -28.15% | 17.9M +98.15% | 9.1M +326.26% | 2.1M +183.33% | |
Cash from Investing Activities | 40.3M -30.72% | 58.2M +208.69% | -53.6M -197.60% | 54.9M +48.41% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -26.6M -3.65% | -27.6M -113.94% | 198.1M +889.00% | 20.0M +550.42% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -130.65% -27.38% | -179.92% +3.86% | -173.23% +20.52% | -143.74% +27.34% | |
Return on Assets | -24.91% -9.95% | -27.67% -13.41% | -31.95% +6.82% | -29.91% +75.09% | |
Return on Equity | -84.63% +26.00% | -67.17% +35.04% | -49.74% +47.22% | -33.78% +82.84% | |
Revenue Growth | -3.42% -76.61% | -14.61% +80.92% | -8.07% -28.19% | -11.24% -45.79% | |
Current Ratio | 4.21 -19.25% | 5.21 -22.60% | 6.73 -35.57% | 10.45 +18.49% | |
Cash Ratio | 0.67 +2.80% | 0.65 -52.42% | 1.36 -7.80% | 1.48 -6.73% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow